Allianz Asset Management GmbH trimmed its stake in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 36.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 184,561 shares of the medical research company’s stock after selling 106,544 shares during the quarter. Allianz Asset Management GmbH owned about 0.29% of PRA Health Sciences worth $14,058,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in PRAH. Aperio Group LLC bought a new position in PRA Health Sciences during the second quarter worth $233,000. Sei Investments Co. boosted its position in PRA Health Sciences by 4.9% during the second quarter. Sei Investments Co. now owns 14,654 shares of the medical research company’s stock worth $1,100,000 after purchasing an additional 690 shares during the period. Schwab Charles Investment Management Inc. boosted its position in PRA Health Sciences by 10.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 234,930 shares of the medical research company’s stock worth $17,623,000 after purchasing an additional 22,303 shares during the period. First Trust Advisors LP boosted its position in PRA Health Sciences by 21.1% during the second quarter. First Trust Advisors LP now owns 100,399 shares of the medical research company’s stock worth $7,531,000 after purchasing an additional 17,519 shares during the period. Finally, Rhumbline Advisers boosted its position in PRA Health Sciences by 48.5% during the second quarter. Rhumbline Advisers now owns 44,149 shares of the medical research company’s stock worth $3,312,000 after purchasing an additional 14,413 shares during the period. 98.49% of the stock is owned by hedge funds and other institutional investors.
In other news, Director Matthew P. Young sold 5,115 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $79.90, for a total value of $408,688.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.10% of the company’s stock.
Shares of PRA Health Sciences Inc (NASDAQ PRAH) opened at $87.23 on Thursday. The stock has a market cap of $5,361.71, a PE ratio of 31.11, a PEG ratio of 1.46 and a beta of 0.40. PRA Health Sciences Inc has a 52-week low of $53.47 and a 52-week high of $88.60. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.01 and a quick ratio of 1.01.
PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.03. The company had revenue of $494.55 million during the quarter, compared to analysts’ expectations of $477.89 million. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. PRA Health Sciences’s quarterly revenue was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.64 earnings per share. sell-side analysts forecast that PRA Health Sciences Inc will post 3.2 EPS for the current year.
A number of research firms have commented on PRAH. BidaskClub raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Thursday. Barclays began coverage on shares of PRA Health Sciences in a research report on Monday. They set an “overweight” rating and a $94.00 price objective for the company. Robert W. Baird set a $94.00 price objective on shares of PRA Health Sciences and gave the stock a “buy” rating in a research report on Friday, December 1st. Mizuho set a $87.00 price objective on shares of PRA Health Sciences and gave the stock a “buy” rating in a research report on Friday, December 1st. Finally, KeyCorp reaffirmed a “buy” rating and set a $93.00 price objective (up from $86.00) on shares of PRA Health Sciences in a research report on Monday, October 30th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $89.50.
TRADEMARK VIOLATION NOTICE: “PRA Health Sciences Inc (PRAH) Position Trimmed by Allianz Asset Management GmbH” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/14/pra-health-sciences-inc-prah-position-trimmed-by-allianz-asset-management-gmbh.html.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.